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bp Base pair 
cAMP Cyclic adenosine monophosphate 
CAMs Constitutively active mutants 
CCL 18 Chemokine ligand 18 
cDNA Complementary DNA 
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ETAR Endothelin-1 type A receptor 
ETAR-IgG IgG targeting ETAR 
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GFP Green fluorescent protein 
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GPCR G-protein coupled receptor 
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IgG Immunoglobulin class G 
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IL-8 Interleukin 8 




MAPK Mitogen-activated protein kinase 
MEKK1 MAPK kinase kinase 1 
mL Milliliter 
mRNA Messenger RNA 
NFAT Nuclear factor of activated T-cells 
nm Nanometer 
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PBS Dulbecco’s phosphate buffered saline 
PCR Polymerase chain reaction 
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PKC Protein kinase C 
qRT-PCR Quantitative Real Time-PCR 
RNA Ribonucleic acid 
ROCK Rho-associated protein kinase 
RT Reverse transcription 
SD Standard deviation 
SEM Standard error of the mean 
SRF Serum response factor 
SSc Systemic sclerosis 
ssDNA Single-strand DNA 
TGF-b Transforming growth factor beta 
TM Transmembrane 
Trp Tryptophan 
TSH Thyrotropin, thyroid stimulating hormone 
TSHR Thyroid stimulating hormone receptor 
Tyr Tyrosine 
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a1aAR Alpha-1A adrenergic receptor 
b1AR Beta-1 adrenergic receptor 







Endothelin-1 type A (ETAR) and B receptors (ETBR) belong to the GPCR subfamily A and mediate 
the actions of their peptide agonist Endothelin-1 (ET-1). ET-1 is one of the most potent 
vasoconstrictors in the human organism and regulates blood pressure and local and systemic 
homeostasis. ETAR can be activated not only by ET-1 but also by agonistic antibodies. As recently 
demonstrated, extracellular binding of agonistic autoantibodies targeting ETAR (ETAR-IgG) 
promotes downstream signaling through allosteric activation of the receptor, independent of ET-1. 
The resultant signaling induced severe renovascular disease, exemplified on systemic sclerosis 
related renal crisis (SSc). Despite their clinical relevance, the potential differences and similarities 
to natural ligand-mediated activation have not been studied yet.  
To investigate relevant extracellular loops required for ET-1 and ETAR-IgG binding and 
downstream signaling responses, each of the three extracellular loops (ECL) was individually 
mutated. Functional effects were assessed with two different assays. The first GPCR activation 
assay relied on the MMY yeast model, in which a single human GPCR controls yeast growth to 
assess the effects of the mutations on ETAR-IgG-mediated ETAR activation. In the second assay, 
luciferase reporter plasmids enabled monitoring of G-proteins binding to ETAR in response to ET-
1 and ETAR-IgG.  
Change of ECL3 structure resulted in the constitutive activation of ETAR both in MMY yeast 
model and in luciferase reporter assays. Besides, mutating ECL1 to Alanine or replacing ECL2 
demonstrated no effect on ETAR-IgG -induced ETAR activation in yeast GPCR activation assay. 
In addition, these mutations did not influence ETAR-IgG -mediated Gq/11 and G12/13 binding to 
ETAR as revealed by luciferase reporter assays. On the contrary, results showed that intact structure 
of ECL1 and ECL2 is necessary for G12/13 activation upon ET-1 stimulation.  
This work demonstrates that unlike similar antibodies against other GPCRs, antibodies directed 
against Endothelin-1 type A receptor do not bind to the extracellular loops of the receptor; thereby 
eliciting intracellular signaling differences from the natural ligand. Elucidation of these epitopes 
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is a prerequisite for rational design of new potent and more precise pharmacological compounds 
to replace old, relatively inefficient ones.  
 9 
Abstrakt 
Endothelin-1 Typ A (ETAR) und B Rezeptoren (ETBR) gehören zur Unterfamilie A der GPCR und 
vermitteln die Signale ihres Peptidagonisten Endothelin-1 (ET-1). ET-1 ist einer der stärksten 
Vasokonstriktoren im menschlichen Organismus und reguliert Blutdruck und lokale und 
systemische Homöostase. ETAR können nicht nur durch ET-1 aktiviert werden, sondern auch 
durch agonistische Antikörper. Wie vor kurzem gezeigt, induziert die extrazelluläre Bindung 
agonistischer Autoantikörper am ETAR (ETAR-IgG) downstream Signaling durch allosterische 
Rezeptoraktivierung unabhängig von ET-1. Dadurch können schwere renovaskuläre 
Erkrankungen ausgelöst werden, wie sich am Beispiel der renalen Krise bei Systemischer Sklerose 
(SSc) zeigt. Trotz ihrer klinischen Bedeutung, wurden die möglichen Unterschiede und 
Ähnlichkeiten zur Rezeptoraktivierung durch den natürlichen Liganden bisher noch nicht erforscht.  
Um die für die Bindung von ET-1 und der ETAR-IgG entscheidenden extrazellulären Schleifen 
und intrazelluläre Signalantworten untersuchen zu können, wurden jede der drei extrazellulären 
Schleifen (ECL) einzeln mutiert. Funktionelle Effekte wurden mit zwei verschiedenen Assays 
überprüft. Der erste GPCR Aktivierungsassay beruhte auf einem MMY Hefemodell, bei dem ein 
einzelner humaner GPCR das Hefewachstum bestimmt. Beim zweiten Assay ermöglichte ein 
Luziferase-Reporterplasmidassay, die Bindung von G-Proteinen an den ETAR nach Stimulation 
mit ET-1 und ETAR-IgG zu monitoren.  
Veränderungen an der Struktur der 3. ECL führten zur konstitutiven Aktivierung des ETAR, sowohl 
im MMY Hefemodell, als auch im Luziferase-Reporterassay. Dagegen blieben die Mutation zu 
Alanin an der 1. ECL oder der Ersatz der 2. ECL ohne Wirkung auf die ETAR-IgG -induzierte 
ETAR Aktivierung im Hefe GPCR Aktivierungsassay. Darüberhinaus beeinflussten diese 
Mutation die ETAR-IgG vermittelte Bindung von Gq/11 und G12/13 an den ETAR nicht, wie in 
Luziferase-Reporterassays gezeigt wurde. Im Gegensatz dazu zeigten die Ergebnisse, dass die 
intakten Strukturen der 1. ECL und 2. ECL für die G12/13 Aktivierung durch ET-1 notwendig sind.  
Diese Arbeiten zeigen, dass anders als bei ähnlichen GPCR-Antikörpern, die gegen den 
Endothelin-1 type A Rezeptor gerichtete Antiköper nicht an die extrazellulären Rezeptorschleifen 
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binden. Dadurch ergeben sich Unterschiede zum intrazellulären Signaling des natürlichen 
Liganden. Die Aufklärung der Bindungsepitope ist die Voraussetzung für die Entwicklung neuer, 
präziser und wirksamerer Medikamente, um die alten, relativ ineffizienten Arzneien zu ersetzen.  
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1 Introduction 
1.1 Endothelin-1 receptors 
G-protein-coupled receptors (GPCR), also known as 7-transmembrane receptors (7-TM), 
comprise the largest receptor family and the most important drug targets, since more than 40% of 
currently used drugs are GPCR modulators. More than 800 human GPCRs are clustered into five 
different classes: rhodopsin, secretin, adhesion, glutamate and frizzled / taste2 [1]. GPCRs 
transduce signals elicited by their endogenous ligands, which range from vasoactive peptides, 
neurotransmitters, chemokines, hormones and fatty acids to physical stimuli such as light [2]. 
Endothelin receptors, Endothelin-1 type A (ETAR) and type B (ETBR) receptors, belong to the 
class A GPCRs and interact in a similar manner with their natural peptide agonist ET-1, but yield 
different signals with a sequence similarity of 63% [3]. The localization of the two receptors is 
different. ETAR is localized in vascular smooth muscle, heart, lung and kidney, whereas ETBR can 
be found in more tissues, mainly in the brain, kidney, liver and lung [4]. ET receptors are 
susceptible to various factors and can be up- or downregulated. Hypoxia, cAMP, epidermal growth 
factor upregulate the ETAR production; Endothelins, Angiotensin II, platelet derived growth factor 
and TGF-b downregulate ETAR expression [5]. 
1.1.1 Endothelin-1 type A receptor 
The gene coding for the human ETA receptor (EDNRA) is located on chromosome 4, which 
contains eight exons and seven introns [6]. The molecular weight of ETAR is about 44 kDa, 
consisting of 427 amino acids; its affinity for ET-1 is higher than for ET-2 and ET-3. Figure 1 
shows the amino acid sequence and structure of ETAR. Mutation of a cluster of five Cys residues 
into either serine or alanine in the cytoplasmic tail did not alter the binding but completely blocked 
palmitoylation of ETAR, which led to a failure of ET-1 to increase the cytoplasmic calcium [7]. 
Deletion of either the entire extracellular N-terminus or the intracellular C-terminus completely 
inactivated ET-1 binding [8]. 
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Figure 1. Schematic diagram of ETAR. 
Typical for a GPCR, the activation of ETAR can initiate downstream physiological and 
pathophysiological processes. Human ETAR can couple with Gq/11, Gs and G12/13. ETAR expressed 
at different levels in CHO cells provide evidence that the coupling of ETAR to Gq/11 and G12/13 
differs depending on the expression level of the receptor, resulting in the activation of different 
signaling cascades [9]. The precise signaling pathways responsible for endothelin-induced 
vasoconstriction are still being actively studied. However, it is widely accepted that the activation 
of phospholipase C, production of inositol triphosphate and mobilization of calcium are the most 
relevant factors. Except for the effects on vascular tone, Endothelins also promote the growth and 
proliferation of vascular smooth muscle cells, which appears to be ETAR-mediated, involving the 
activation of mitogen-activated protein (MAP) kinases and the transactivation of epidermal growth 
factor receptor [10].  
In 2016, crystal structure and conformational changes of human Endothelin-1 type B Receptor 
(ETBR) with and without its ligand ET-1 was reported [11]. However, the crystal structure of ETAR 
remains unsolved. Due to the low expression levels and poor stability, crystallization and GPCRs 
structure determination studies are difficult to perform. Another way to study the structure of a 
GPCR is to change all amino acids of the GPCR individually or in a group. Amino acids are often 
replaced by Alanine, due to its high helix propensity and low probability of steric hindrance [12]. 
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Such studies have been performed on ETAR. Eighteen amino acids were mutated and analyzed for 
binding of Endothelin-1 and Bosentan, an inhibitor of both ETA-and ETBR. It has been observed 
that single point mutations differentially affect binding of agonist and antagonist [13]. In the N-
terminus of ETAR, two mutants containing D46N or R53Q substitutions showed dramatically 
reduced binding to ET-1, indicating that the substitutions of single amino acid alter the three-
dimensional structure of the ligand-binding domain of the receptor [14]. Furthermore, it has been 
reported that Tyr129 is important for the peptide ligand affinity and selectivity of ETAR [15].  
1.1.2 Endothelin-1 type B receptor 
The gene coding for the human ETB receptor (EDNRB) is located on chromosome 13 and contains 
seven exons and six introns [16]. The molecular weight of ETBR is 32 kDa and consists of 442 
amino acids with same affinity for the three Endothelins. In 2016, Shihoya and co-workers 
reported the amino acid sequence, crystal structure and conformational changes of ETBR in its 
ligand-free form and complexed with ET-1 [11]. When ETBR interacts with ET-1, the N-terminus, 
the three extracellular loops and six transmembrane helices (2-7) are fully occupied. ETBR has a 
fundamental role in renal, pulmonary, coronary, cerebral and systemic circulation. ETBR in the 
endothelium mediates the release of vessel relaxants such as nitric oxide, prostacyclin and 
endothelium-derived hyperpolarizing factors; it  also plays an essential role in the clearance of ET-
1 [17]. 
1.2 Endothelin-1, a natural peptide agonist of Endothelin-1 receptors 
1.2.1 Synthesis of Endothelin-1 
Endothelins are 21-amino acid peptides that are mainly produced in the endothelium and have a 
molecular weight of about 2.5 kDa. There are three isoforms (ET-1, ET-2 and ET-3), each with 
different gene and tissue distributions. In healthy individuals, there is a subtle balance between 
vasoconstriction and vasodilation, but when ET-1 is overexpressed, it can cause vascular diseases 
in various organ systems [18]. The gene coding for human ET-1 is located on chromosome 6 with 
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a total length of 1246 base pairs. This gene product is a 212-amino acid preproET that is first 
converted intracellularly into an inactive pro-endothelin peptide, after the signal peptide has been 
removed, and then, in the case of ET-1, into the 38-amino acid long bigET. The bigET is then 
finally converted into the active form of the peptide and a C-terminal fragment by the endothelin-
converting enzyme (ECE) [19] (Figure 2).  
 
Figure 2. Pathways of endothelin-1 synthesis and sites of action [19] 
Under normal physiological condition, the amount of circulating ET-1 is 0.26-5 ng/L [20], and 
ET-1 is eliminated from circulation with a half-life of one to seven minutes	[21].  
1.2.2 Physiological effects of Endothelin-1 
ET-1 affects virtually every system that regulates blood pressure and local and systemic 
homeostasis. It is the strongest vasoconstrictor yet identified, at least 10-fold stronger than 
Angiotensin-II and 100-fold stronger than Norepinephrine [20]. The constrictor response caused 
by ET-1 can last for a considerable period, of several hours [22]. ET-1 plays a major role in the 
regulation of vascular function. Under physiological conditions, ET-1 induces sustained 
vasoconstriction of smooth muscle cells [23]. ET-1 maintains the basic vascular tone, modulates 
endothelin biosynthesis, and regulates water balance [24]. In the endothelin system, ET-1 regulates 
multiple renal functions like renal blood flow, glomerular filtration rate, salt and water excretion, 
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acid/base treatment and extracellular matrix accumulation [25]. ET-1 increases the release of 
superoxide anion products and cytokines, which contribute to the development of the inflammation 
[26], and it has also been shown to be involved in immune functions [27]. 
1.2.3 Structure of Endothelin-1 
ET-1 adopts a bicyclic structure with two disulfide bonds consisting of four cysteines (Cys1-Cys15 
and Cys3-Cys11) (Figure 3); it has six hydrophobic amino acids at its C-terminus called 
hydrophobic tail, both of which are important for ET-1 to maintain its activity. It has been shown 
that some residues at positions 18, 19 and 21 are crucial for ET-1 binding to the receptors. The 
deletion or substitution of Trp21 leads to the loss of receptor binding and activation [28]. An α-
helical structure is formed between the central residues and the N-terminus, which is firmly 
attached to the α-helix through the disulfide bonds [3]. The N-terminus and α-helical regions of 
ET-1 have a fairly stable conformation, while the C-terminus is flexible and has an extended 
conformation [29]. 
 





1.3 Autoantibodies targeting ETAR 
1.3.1 Autoantibodies targeting ETAR in obliterative vasculopathies 
ETAR mediates the vasoconstrictive properties of ET-1 [31]. Functional autoantibodies have been 
involved in the pathogenesis of vascular lesions in renal and heart transplantation in the absence 
of donor specific-antibodies [32-34]. Banasik M et al. evaluated the presence of non-HLA 
antibodies (anti-Angiotensin II type 1 receptor (AT1R) and/or anti-ETAR) in 65 renal transplant 
patients. It was shown that 10.7% of the patients had a high level of non-HLA antibodies and graft 
loss in these patients was significantly higher. In another study conducted by the same group, the 
presence of ETAR-IgG was evaluated in 116 renal transplant recipients. Anti-ETAR antibodies 
were observed in 47.4% of the patients and the function of the renal transplant was significantly 
worse in these patients. Hiemann et al. tested the impact of antibodies targeting AT1R and ETAR 
in 30 heart transplant recipients. They demonstrated that elevated levels of antibodies against 
AT1R and ETAR were associated with cellular and antibody-mediated rejection. ETAR-IgG have 
also been involved in the pathogenesis of systemic sclerosis (SSc) [35]. 
1.3.2 Autoantibodies targeting ETAR in systemic sclerosis 
1.3.2.1 Clinical manifestations 
Systemic sclerosis (SSc), also known as Scleroderma, is a chronic autoimmune and vascular 
disease of systemic connective tissue. Pulmonary and renal involvements are the leading causes 
of death in patients with SSc [36]. About 5-10% of diffuse SSc patients present with internal organ 
lesions at some point during the course of the disease and patients with  greater and rapid skin 
lesions have the highest risk of developing renal complications [37]. Although therapies can 
alleviate some of the symptoms, there are no specific medications or therapies to reverse or control 




1.3.2.2 Pathogenesis and involvement of ETAR-IgG 
The difficulties in diagnosing and treating SSc are due to the complexity of the pathology of the 
disease, which involves interactions between the immune system, vascular system and connective 
tissue [38]. Extensive fibrosis, which is associated with diffuse small vessel vasculopathy, is 
unique and distinguishing in SSc [39]. Both vascular damage and activation of endothelial cells 
are prominent, and even occur before the fibrosis [40]. Microvasculature lesions involve mainly 
progressive thickening of the vessel wall, large gaps between endothelial cells, loss of vascular 
endothelium integrity, endometrial fibrosis, and hyperplasia, resulting in microthrombus formation 
leading to vascular occlusion and tissue hypoxia [41]. In addition, vascular repair and angiogenesis 
in SSc are found to be defective, leading to vasoconstriction and chronic clinical conditions in the 
affected area [42]. Several vasoactive peptides are involved in the pathogenesis of SSc, such as 
Endothelin-1[43]. Increased level of ET-1 has been reported in SSc patients [44] and elevated ET-
1 levels are associated with renal failure [45]. Bosentan, an Endothelin-1 receptor blocker, can 
alleviate some of the vascular manifestations of SSc [46]. 
ETAR-IgG were detected in most SSc patients with progressive vasculopathy; higher autoantibody 
levels were associated with more severe late complications and higher mortality [35]. This makes 
the detection and quantification of autoantibodies an important part of the diagnosis and treatment 
of SSc. ETAR-IgG in SSc are not only associated with vascular complications, but may also be 
part of alloimmune and fibrotic complications that induce T cell migration and produce more 
interleukin 8 (IL-8) and chemokine ligand 18 (CCL18) [47]. In vitro ETAR-IgG induced receptor-
mediated ERK1/2 phosphorylation and increased TGF-β gene expression in HMECs [35]. ETAR 
antibodies increase endothelial Ca2+ concentration and their action can be blocked in vivo by 
specific antagonist. In patient sera, anti-ETAR IgG are more common in SSc-associated pulmonary 






2 Hypothesis and Objectives 
2.1 Hypothesis 
Autoantibodies targeting the Endothelin-1 type A receptor (ETAR) have been detected in systemic 
sclerosis (SSc) and contribute to the pathogenesis of the disease and its clinical severity. Both the 
receptor natural peptide agonist, Endothelin-1 (ET-1), and antibodies targeting ETAR and isolated 
from SSc patients, ETAR-IgG, activate ETAR and trigger downstream intracellular signaling. 
However, binding sites and downstream intracellular signaling might differ substantially between 
patients´ ETAR-IgG and natural peptide agonist. A thorough knowledge of the cellular 
mechanisms of antibody-mediated receptor activation is necessary to provide further insights for 
the development of therapeutic strategies to block specifically the action of the antibodies and to 
understand specific pathways. Hence, the study aim of this thesis was to test the hypothesis that 
ETAR-IgG isolated from SSc patients bind differently to ETAR as ET-1 with a binding occurring 
on the extracellular domains of the receptor and induce other cellular responses than the peptide 
agonist. 
2.2 Objectives 
1. To test the first hypothesis that ETAR-IgG bind to extracellular domains of the receptor, different 
mutants of ETAR disturbing the structure of one of the three extracellular loops had to be created. 
Thus, ECL1 and -3 were mutated to Alanine to suppress folding and charge. To study ECL2, a 
construct, where ECL2 of ETAR has been replaced by Angiotensin II type 1 receptor (AT1R) 
second extracellular loop, was already available in the laboratory [Development of a molecular 
toolbox to study the cross-talk between Angiotensin II type 1 and Endothelin-1 type A receptors 
in the context of obliterative vasculopathy, http://www.diss.fu-
berlin.de/diss/receive/FUDISS_thesis_000000100230]. 
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2. A GPCR activation assay already developed in the laboratory had to be optimized to study the 
binding of the antibodies to ETAR and the receptor´s activation in presence or absence of the ECLs 
mutations.  
3. To investigate ETAR-IgG effects on downstream signaling in comparison to natural peptide 
agonist ET-1, human microvascular endothelial cells (HMEC-1) were chosen as a mammalian cell 
model and luciferase reporter assays were performed to determine specific G-protein involvements. 
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3 Materials and methods 
3.1 Materials 
3.1.1 Chemical substances 
Chemicals and solutions Manufacturer 
1 kb DNA ladder Thermo Fisher Scientific 
2-Propanol Carl Roth 
3-amino-1,2,4-triazole (3-AT) Sigma 
5X Passive Lysis Buffer (PLB) Promega 
10X M-MuLV Reverse Transcriptase Buffer New England BioLabs 
10X Trypsin-EDTA PAA 
Agarose Serva 
Ampicillin Alkom  
Bacto Agar BD 
Bacto Peptone BD 
Bacto Trypton BD 
Bacto Yeast Extract BD 
Bis-Tris AppliChem 
Blasticidin S InvivoGen 
Dimethyl sulphoxide (DMSO) Sigma Aldrich 
dNTP mix Thermo Fisher Scientific 
Dulbecco's Modified Eagle's medium (DMEM) 
4.5g/LGlucose 
BioWest 
DMEM 1.5 g/L Glucose BioWest 
Dulbecco’s Phosphate Buffered Saline (PBS) Biochrom 
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Chemicals and solutions Manufacturer 
Dextrose (D(+)-Glucose) Applichem 
Ethylenediamintetra-acetic acid (EDTA) Carl Roth 
Ethanol 99.8% Carl Roth 
Ethanol 96% (MEK, denaturated) Herbeta Arzneimittel 
FastStart Universal SYBR Green Master Roche 
Fetal calf serum (FCS) Gibco 
Fluorescein-D-glucopyranoside (FDGlu)  Invitrogen 
Gelatin Sigma  
Glycerin Carl Roth 
hEGF Sigma Aldrich 
Hydrocortisone Sigma Aldrich 
L-Glutamine PAA 
L-arginine (HCl) Applichem 
L-aspartic acid Applichem 
L-glutamic acid (monosodium) Applichem 








Lithium acetate Applichem 
MCDB-131 c.c. pro GmbH 
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Chemicals and solutions Manufacturer 
Midori Green Advance DNA Stain NIPPON Genetics 
M-MuLV Reverse Transcriptase New England BioLabs 
NaCl Solution Lonza 
Oligo d(T) 16 Invitrogen 
PEG 3350 Sigma Aldrich 
Penicillin/Streptomycin (P/S) PAA 
RNase inhibitor Thermo Fisher Scientific 
SeaKem LE Agarose Lonza 
single-stranded DNA (ssDNA) Sigma Aldrich 
SOC Medium Clontech 
Sodium chloride Carl Roth 
Sodium hydroxide Sigma Aldrich 
Trypan blue Sigma Aldrich 
Tris Carl Roth 
Tris-HCl Sigma Aldrich 




Applied Biosystems® 7500 Real-Time PCR System Thermo Fisher Scientific 
Axiovert 40 CFL Microscope Carl Zeiss 
Biofuge primo R Thermo Fisher Scientific 
Digital Heatblock II VWR 
FLUOstar OPTIMA Microplate Reader BMG LABTECH 
 23 
FRESCO 21 Centrifuge Thermo Electron Corporation 
HERA cell 240 Incubator Thermo Electron Corporation 
HERA safe Microbiological Safety Cabinet Thermo Electron Corporation 
Heraeus / BB 6220 CU O2 Thermo Fisher Scientific 
Incubator B28 BINDER 
Incubating Orbital Shaker professional 3500 VWR 
ND-1000 Spectrophotometer VWR 
Perfusor secura FT Braun 
Polymax 1040 T Platform Shaker Heidolph 
SUB Waterbath Grant 
T Professional BASIC XL 96 Thermocycler Biometra 
UV-transilluminator Gene Flash SYNGENE 
3.1.3 Kits 
Kits Manufacturer 
Direct-zolTM RNA MiniPrep Zymo Research 
GeneJET Plasmid Miniprep Kit  Thermo Fisher Scientific 
HiTrap Protain G HP      GE Healthcare 
In-Fusion ® HD Cloning Kit  Takara 
Luciferase Assay System Promega 
NucleoBond®Xtra Midi/Maxi Takara 
NucleoBond®Xtra Midi/Maxi EF Takara 
PeqGOLD MicroSpin Cycle pure Kit PEQLAB 
Q5® Site-Directed Mutagenesis Kit New England BioLabs 
Xfect Transfection Reagent  Takara 
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3.1.4 Plasmid, bacteria, cell line, yeast strains and enzymes 
Plasmid Manufacturer 
p426 GPD GlaxoSmithKline 





NEB 5-alpha Competent E.coli Cells New England BioLabs 
Stellar competent Cells  Takara 
  
Cell line Manufacturer  
Human Microvascular Endothelial Cells (HMEC-1) 
Kindly given by 
Dr. H.D. Orzechowski 
  
Yeast strains Manufacturer 
MMY 12 GlaxoSmithKline 
MMY 14 GlaxoSmithKline 
  
Enzymes and provided buffer Manufacturer  
HindIII-HF New England BioLabs 
XhoI New England BioLabs 
CutSmart Buffer New England BioLabs 
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3.1.5 Agonist  
Agonist  Manufacturer 
Endothelin 1 human and porcine Sigma Aldrich 
3.1.6 Buffer recipes 
Buffer Reagent Final conc. 
3-AT 3-amino-1,2,4-triazole 1 M 
 In H2O  
50% PEG PEG3350 50% m/v 
 In H2O  
 Filtered (0.45 µm)  
Ampicillin stock solution Ampicillin powder 100 mg/mL 
 In H2O  
 Filter sterilized (0.22 µm)  
Binding buffer, pH 7.0 Na2HPO4 20 mM 
 In H2O  
 Filtered (0.45 µm)  
BU salts 10X, pH 7.0 Na2HP04.7H2O 7% m/v 
 NaH2PO4 3% m/v 
 In H2O  
 Sterilized by autoclaving  
DNA sample loading buffer 6x Glycerol 30% v/v 
 Xylene cyanole 0.25% v/v 
 Bromphenolblue 0.25% m/v 
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Buffer Reagent Final conc. 
 In H2O  
Elution buffer, pH 2.7 Glycin-HCl 0.1 M 
 In H2O  
 Filtered (0.45 µm)  
Gelatin stock solution gelatin  2% m/v 
 In PBS  
 Sterilized by autoclaving  
Histidine 100X L-Histidine 2 mg/mL 
 In H2O  
 Filter sterilized (0.22 µm)  
LiAc Lithium acetate 1 M 
 In H2O  
 Filter sterilized (0.22 µm)  
LiAc-TE LiAc 0.1 M 
 TE 10x 10%v/v 
 In H2O  
LiAc-PEG-TE LiAc 0.1 M 
 TE 10x 10%v/v 
 50% PEG 80% v/v 
Neutralization buffer, pH 9.0 Tris-HCl 1 M 
 In H2O  
 Filtered (0.45 µm)  
PBS (Ca2+- /Mg2+ -free), pH 7.3 NaCl 137 mM 
 KCl 2.7 mM 
 Na2HPO4 9 mM 
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Buffer Reagent Final conc. 
 KH2PO4 2.3 mM 
 In H2O  
 Sterilized by autoclaving  
PLB 1X PLB 5X 20%v/v 
 In ddH2O  
TBE buffer 1X, pH 8.0 Tris 89 mM 
 Boric acid 89 mM 
 EDTA 2 mM 
 In H2O  
TE buffer 10X Tris-HCl, pH 7.5 0.1 M 
 EDTA 0.01 M 
 In H2O  
3.1.7 Media 
Bacteria media 
Lysogeny broth (LB) medium Conc. 
Bacto tryptone  1% m/v 
Bacto yeast extract  0.5% m/v 
NaCl  1% m/v 
  add Milli-Q water 
 Sterilize by autoclaving  
   
LB agar  Conc. 
Bacto tryptone  1% m/v 
Bacto yeast extract  0.5% m/v 
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NaCl  1% m/v 
Bacto agar  1.5% m/v 
  add Milli-Q water 
 Sterilize by autoclaving  
Cell culture media 
Complete medium Conc. 
L-glutamine 10 mM 
hEGF  10 ng/mL 
Hydrocortisone 10 nM 
FCS 5% v/v 
Penicillin 100 U/mL 
Streptomycin 100 µg/mL 
 add MCDB-131 
  
Starvation medium Conc. 
L-glutamine  10 mM 
hEGF   10 ng/mL 
Hydrocortisone  10 nM 
FCS  0.5% v/v 
Penicillin  100 U/mL 
Streptomycin  100 µg/mL 
 add MCDB-131 
Yeast media 
WHAUL powder  Conc. 
L-arginine (HCl)  1.2 g 
 29 
L-aspartic acid  6.0 g 
L-glutamic acid (monosodium)  6.0 g 
L-lysine  1.8 g 
L-methionine  1.2 g 
L-phenylalanine  3.0 g 
L-serine  22.5 g 
L-threonine  12 g 
L-tyrosine  1.8 g 
L-valine  9.0 g 
 
40% Glucose  Conc. 
Dextrose  40% m/v 
 Filtered (0.45 µm)  
   
YNB 10X  Conc. 
yeast nitrogen base without AA  6.7% m/v 




WHAUL medium, pH 7.0 Conc. 
WHAUL powder  1.1 g 
  Milli-Q water 850 mL 
 Sterilize by autoclaving  
 Supplemented with  
YNB 10X  10%v/v 
40% glucose  5%v/v 
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WHAUL agar, pH 7.0  Conc. 
WHAUL powder  1.1 g 
Bacto agar  20 g 
  Milli-Q water 850 mL 
 Sterilize by autoclaving  
 Supplemented with  
Histidine 100X  10% v/v 
YNB 10X  10% v/v 
40% glucose  5% v/v 
   
FDGlu assay medium, pH 7.0 Conc. 
BU salts 10X  10%v/v 
FDGlu  10 µM 
3-AT  2 mM 
  add WHAUL medium 
   
YPD medium  Conc. 
Bacto peptone  2% m/v 
Bacto yeast extract  1% m/v 
dextrose  2% m/v 
  add Milli-Q water 
 Sterilize by autoclaving  
   
YPD agar  Conc. 
Bacto peptone  2% m/v 
 31 






  add Milli-Q water 
 Sterilize by autoclaving  
3.1.8 Primers 
Primers for mutagenesis experiments were designed with the NEBaseChangerTM software online. 
All primers were provided by Biolegio (the Netherlands). Primers used to generate the constructs 
are listed in Table 1, primers for subcloning in Table 2, primers for sequencing in Table 3 and 
primers for quantitative Real Time-PCR (qRT-PCR) in Table 4. 
Constructs name 5'- to -3' 
ETAR ECL1 Ala 
F: tgccgctgccgctgccGTATTTCTTTGCAAGCTGTTC 
R: gcagcagccgcggccgcAGCCAGCAGCTTAAATAC 
ETAR ECL3 Ala 
F: gcggccgcagctgcagcagctAGTTTCTTACTGCTCATGG 
R: ggccgctgcggcagccgcagcTTTCTTCAATATACGGCTTAAG 







Table 1. Primers for constructs generation 
 




Table 2. Primer for subcloning 
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Sequencing primers 5'- to -3' 
p426GPD (from nucleotides 4025 to 4046)  Forward: TTGACCCACGCATGTATCTATC 
pcDNA cmv (from nucleotides from 769 to 789) Forward: CGCAAATGGGCGGTAGGCGTG 
ETAR (from nucleotides 446 to 465) Forward: ATCACAATGACTTTGGCGTA 
ETAR (from nucleotides 715 to 734) Forward: TGTATGCTCAATGCCACATC 
Table 3. Primers for sequencing  
 
Primers for qRT-PCR Sequence 
Human EDNRA se gATAgCCAgTCTTgCCCTTg 
Human EDNRA ase CAgAggTTgAggACggTgAT 
Yeast GAPDH se AGACTGTTGACGGTCCATCC 
Yeast GAPDH ase CAACAGCGTCTTCGGTGTAA 
Table 4. Primers for quantitative Real Time-PCR 
3.2 Methods 
3.2.1 Generation of constructs 
3.2.1.1 Preparation of the linearized vector by restriction enzyme digestion 
One µg of the plasmid was linearized using two appropriate restriction enzymes in the requested 
digestion buffer in a 50 µL reaction. Samples were incubated at 37°C for three hours and digestion 
was verified on an agarose gel.  
3.2.1.2 Agarose gel electrophoresis  
0.9% agarose gel was prepared in 1X TBE. 5µL of Midori Green was added to every 100mL of 
gel. The solid gel was placed into a gel electrophoresis apparatus filled with 1X TBE. Samples 
were mixed with 6X agarose gel loading buffer to 1X final. DNA marker (1 kb DNA ladder) was 
run together with the samples as a molecular weight indicator. Samples were migrated at 100 V 
for 45 minutes and examined under ultraviolet light at 302 nm using an UV-transilluminator. 
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3.2.1.3 Purification of digested vector 
The digested plasmid was purified with a PeqGOLD MicroSpin Cycle-pure kit according to the 
manufacturer’s instructions. After purification, the vector was free of enzymes and ready to be 
directly used for ligation. The concentration was measured using a NanoDrop® 
Spectrophotometer. 
3.2.1.4 PCR amplification of target fragment 
To subclone a PCR product into the digested plasmid, In-Fusion cloning kit was used according 
to the manufacturer’s instructions. Amplification of the DNA target was performed with 
CloneAmp HiFi PCR Premix, which contains dNTPs and optimized buffer, allowing rapid set-up 
of PCR reactions. The PCR reaction components are listed in Table 5 and the reaction conditions 
are shown in Table 6. PCR primers were designed for the target gene with 5’ 15-bp extensions that 
are homologous to the ends of the linearized vector (Table 2). The PCR product was verified on 
an agarose gel. 
Reagent Volume/Quantity Final conc. 
CloneAmp HiFi PCR Premix 12.5µL 1X 
10 µM Forward Primer 5 pmol 0.2 µM 
10 µM Reverse Primer 5 pmol 0.2 µM 
Template < 100 ng 20 ng 
Sterilized distilled water up to 25 µL  
Table 5. Master Mix components 
Temperature Time Amplification cycle 
98°C 10 sec  
60°C 15 sec X 35 cycles 
72°C 30 sec  
Table 6. Reaction conditions 
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3.2.1.5 Set up of In-Fusion cloning reaction 
The In-Fusion HD Cloning kit enables fast, directional cloning of one fragment of DNA into any 
vector. The PCR product generated in the previous step was first treated with the Cloning Enhancer 
in order to be purified. The In-Fusion Enzyme was then used to fuse the DNA fragment and the 
linearized vectors effectively and precisely by recognizing 15-bp overlaps at their ends. The 
reaction components are listed in Table 7 and the procedures were performed according to 
manufacturer’s instructions. 
Component Volume 
5X In-Fusion HD Enzyme Premix 2 µL 
Linearized Vector 1µL 
Cloning Enhancer Treated PCR Insert 1µL 
dH2O 6 µL 
Table 7. In-Fusion cloning reaction 
3.2.1.6 Bacterial transformation 
Foreign DNA can be introduced into bacteria by transformation; this enables plasmid 
amplification and an easy collection. By exposing competent cells to a 42°C heat shock, a pressure 
difference between the outside and the inside of the cell is created. This leads to the formation of 
pores in the membrane, through which supercoiled plasmid DNA can easily enter. Followed by 
incubation on ice, the cell wall is closed and the plasmids are kept inside. StellarTM Competent 
Cells (Table 8) were used for the transformation. 2.5 µL of the cloning product was added to 50 
µL of bacteria and the transformation steps were performed according to the manufacturer’s 
instructions. The vectors employed contained an ampicillin resistant gene, conferring antibiotic 
resistance to all bacteria containing the plasmid, allowing them to grow on ampicillin plates (100 




Bacteria Provider Genotype 
Stellar™Competent Cells Takara 
F-, endA1, supE44, thi-1, recA1, relA1, gyrA96, phoA, Φ80d lacZΔ M15, 
Δ(lacZYA-argF) U169, Δ(mrr-hsdRMS-mcrBC),ΔmcrA,λ- 
Table 8. Bacteria genotype 
3.2.1.7 Mini-prep 
A pre-culture of LB medium containing 100 µg/mL ampicillin was inoculated with a single colony 
picked from the LB-Ampicillin agar plate containing the bacteria transformants. 3 mL of the pre-
culture was centrifuged at room temperature. All steps were carried out according to the GeneJET 
Plasmid Miniprep Kit protocol. The nucleic acid concentration was measured by NanoDrop® 
Spectrophotometer. The plasmids were stored at -20°C. 
3.2.1.8 Screening for positive plasmids 
Plasmids isolated by mini-prep were digested by the two restriction enzymes used to linearize 
the vector in a 25 µL reaction. Samples were incubated at 37°C for three hours and then run on 
an agarose gel. Plasmids showing two bands corresponding to the molecular size of the vector 
and the insert were considered positive. 
3.2.1.9 DNA sequencing and alignment  
The plasmids potentially containing the insert were sequenced by the company LGC Genomics 
GmbH using appropriate primers (Table 3). The resulting sequences were analyzed by using the 
DNASTAR MegAlign 14 software. 
3.2.1.10 Midi-prep 
The NucleoBond® Xtra Midi/Maxi and Endotoxin Free (EF) kits were used to extract a large 
amount of plasmid DNA for mammalian cell and yeast experiments. After sequencing, one single 
positive colony was incubated in LB medium with 100 µg/mL ampicillin for eight hours. This pre-
culture was then diluted 1 to 1000 into 100 mL LB medium containing 100 µg/mL 
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incubated overnight at 37°C under shaking. The High-copy protocol was performed according to 
manufacturer’s instructions. After elution and precipitation, plasmid DNA was dissolved in Tris 
buffer. The nucleic acid concentration was measured by NanoDrop® Spectrophotometer. The 
plasmids were stored at -20°C for further use. 
3.2.1.11 Bacterial glycerol stock 
Glycerol stocks enable long-term storage of bacteria. A pre-culture of LB medium containing 100 
µg/mL ampicillin was inoculated with the colony to be preserved and shaken six hours at 37°C. 
250 µL of the pre-culture was added to 750 µL of 60% glycerol and gently mixed. Then the 
glycerol stock was frozen at -80°C. 
3.2.2 Generation of mutated constructs 
3.2.2.1 Site-directed mutagenesis 
Mutated constructs were generated using the Q5® Site-Directed Mutagenesis Kit according to the 
manufacturer’s instructions. Briefly, exponential amplification of cDNA fragment encoding ETAR 
was performed with Q5 Hot Start High-Fidelity DNA Polymerase along with specific primers 
designed using NEBaseChanger (Table 1). The forward primer was designed to incorporate the 
desired nucleotide change in its center, and also to include at least 10 complementary nucleotides 
on the 3’ side of the mutation. The reverse primer was designed to anneal back to back at the 5’ 
ends of the two primers. The experimental conditions of PCR are listed in Tables 9, 10 and 11. 
The PCR products were then treated with the Kinase-Ligase-Dpnl (KLD) enzyme, which enables 
a quick circularization and template removal at room temperature (Table 12). Transformation into 
high-efficiency NEB 5-alpha-Competent E. coli ensures high numbers of transformants on LB-
Ampicillin plates. The transformation was performed using NEB 5-alpha-Competent E.coli (Table 
13). The procedure was the same as described in 2.2.1.6. 
Component 25µL RXN Final conc. 
Q5 Hot Start High-Fidelity 2X Master Mix 12.5µL 1X 
10 µM Forward Primer 1.25µL 0.5 µM 
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Component 25µL RXN Final conc. 
10 µM Reverse Primer 1.25µL 0.5 µM 
Template DNA 1µL 1-25 ng 
Nuclease-free water 9.0µL  
Table 9. Reaction components  
Construct DNA template DNA quantity 
ETAR ECL1 Ala p426 GPD ETAR wild type plasmid 10 ng 
ETAR ECL3 Ala p426 GPD ETAR wild type plasmid 10 ng 
ETAR with ECL2 of AT1R p426 GPD ETAR wild type plasmid 10 ng 
Table 10. Components of PCR reactions for the different constructs  
Construct Second denaturation Annealing Elongation step 
ETAR ECL1 Ala 98°C 10 s 67.6°C 30 s 72°C 6min 
ETAR ECL3 Ala 98°C 10 s 60°C 30 s 72°C 6min 
ETAR with ECL2 of AT1R 98°C 10 s 70°C 30 s 72°C 4min 
Table 11. PCR conditions for the different constructs 
Components Volume Final conc. 
PCR Product 1 µL  
2X KLD Reaction Buffer 5 µL 1X 
10X KLD Enzyme Mix 1 µL 1X 
Nuclease-free Water 3 µL  
Table 12. KLD treatment components 




fhuA2, Δ(argF-lacZ) U169, phoA, glnV44, Φ80Δ(lacZ)M15, gyrA96, recA1, 
relA1, endA1, thi-1, hsdR17 
Table 13. Bacteria genotype 
After transformation, clones were amplified and sequenced as described in 2.2.1.7 to 9. A midi-
prep was performed to produce appropriate quantities of the plasmids as described in 2.2.1.10. 
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3.2.3 Patient IgG isolation 
The isolation of immunoglobulins class G (IgG) was carried out from plasma of patients suffering 
from systemic sclerosis. These patients were tested positive for the presence of antibodies targeting 
ETAR (ETAR-IgG). Plasma was filtered through 0.45 µm filters before use. HiTrap Protein G HP 
columns packed with Protein G SepharoseTM High Performance, which can strongly bind to the 
Fc region of IgG were used for the isolation. After the plasma was diluted 1:2 with binding buffer 
run through the column, the ETAR-IgG solution was eluted, neutralized and dialyzed against 
WHAUL medium or DMEM low glucose, depending on whether the stimulation was performed 
on yeasts or mammalian cells. After dialysis, aliquots of the IgG were sent to Labor Berlin and the 
concentrations were measured by ELISA. 
3.2.4 GPCR activation assay in yeast 
The yeast GPCR activation assay in yeast is well-established as an experimental system for the 
detection of receptor activation [49] [50] [51]. Mating in haploid yeast cells is stimulated by 
pheromone binding to GPCRs. The MMY yeast strains provided by the GlaxoSmithKline 
Company were modified to express chimeric G-proteins, in which the five C-terminal residues of 
Gpa1p were replaced by the corresponding sequence of the human Gα subunits (Table 14). 
Furthermore, these yeasts do not express the yeast GPCR anymore but depend on the expression 
of a human GPCR, able to bind to the yeast chimeric G-protein in order to grow.  
Strain Genotype 
MMY11 
MATa his3 leu2 trp1 ura3 can1 gpa1∆::ADE2 far1∆::ura3 sst2∆::ura3∆ fus1::FUS1-HIS3 
LEU2::FUS1-lacZ ste2∆::G418R [49] 
MMY14 MMY11 TRP1::Gpa1/Gαq(5) [51] 
Table 14. Genotypes of yeast strains used for GPCR activation assay 
3.2.4.1 Yeast transformation 
The procedures are similar to the ones described by Dr. med. Nan Zhu in her thesis [Development 
of a molecular toolbox to study the cross-talk between Angiotensin II type 1 and Endothelin-1 type 
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A receptors in the context of obliterative vasculopathy, http://www.diss.fu-
berlin.de/diss/receive/FUDISS_thesis_000000100230]. Briefly, yeasts were recovered from -
80 °C and spread on a YPD plate. A single colony was put into YPD medium and incubated 
overnight at 30°C, as a pre-culture. On the next day, 100mL of YPD medium was inoculated and 
the yeasts were harvested after two to three hours. Transformation was performed using the lithium 
acetate (LiAc)/ single-stranded DNA (ssDNA)/ polyethylene glycol (PEG) method. Transformed 
yeast cells were plated on WHAUL-His plates and incubated for three or four days.  
3.2.4.2 Measuring gene expression in yeast 
Yeast transformation with different amounts of plasmid was performed. Colonies were picked 
after three or four days and incubated in 3 mL YPD medium at 30°C overnight under shaking. 
Yeast samples were obtained on the next day by centrifugation. The total RNA was extracted using 
Direct-zolTM RNA MiniPrep, which can provide a streamlined method for purification of up to 
100 µg per prep of high-quality RNA directly from samples. The RNA concentration was 
measured by NanoDrop® Spectrophotometer. Reverse Transcription (RT)-PCR was performed to 
obtain cDNA, the RT-PCR components are shown in Table 15. Quantitative Real Time-PCR 
(qRT-PCR) using Applied Biosystems® 7500 qRT-PCR System was performed, components are 
shown in Table 16. The amount of fluorescence released during amplification cycle is proportional 
to the relative quantity of mRNA initially present. 
Content Volume (1X) / Amount 
10X M-MuLV Reverse transcriptase Buffer 5µL 
dNTP mix 10 mM 8µL 
RNase inhibitor 1µL 




Table15. RT-PCR system 
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Content Volume (1X) 
SYBR Green 4µL 
Primer se 10 µM 0.5µL 




Table16. qRT-PCR system 
3.2.4.3 Yeast GPCR assay 
Four days after transformation, four clones from transformed yeasts were picked-up and 
transferred individually into WHAUL medium containing Histidine and incubated overnight at 
30°C under shaking. Each pre-cultured clone was then added to FDGlu assay medium (lacking 
Histidine) containing different concentrations of ETAR-IgG (0, 0.5, 1.0 and 1.5 mg/mL) in 96-well 
plates. 3-AT in the FDGlu assay medium is a competitive inhibitor of the HIS3 enzyme which can 
regulate background activity caused by leakiness of the reporter or constitutive activity of the 
GPCR. Plates were protected from light and incubated at 30°C under shaking. After incubation for 
16 hours, fluorescent measurement was performed at an excitation of 485 nm and emission of 535 
nm.  
3.2.5 Luciferase reporter assay 
Activation of Gq/11 or G12/13 can be monitored with the binding of specific transcription factors, 
NFAT and SRF to the luciferase promoter.  
3.2.5.1 Human microvascular endothelial cells (HMEC-1) 
HMEC-1 cells were grown in flasks with complete growth medium in a humidified atmosphere 
with 5% CO2 at 37 °C. T75 flasks and 24 wells plates were pre-coated with 0.2% gelatin. The cells 
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were passaged at 90 % confluence and used to seed 24 wells plates for the experiments. Cells were 
briefly washed once with PBS, then deattached with 1X Trypsin added into the flask for five 
minutes. Complete medium was used to deactivate the enzyme. After centrifugation and 
resuspension in complete medium, the cells were counted with a Neubauer cell chamber in the 
presence of Trypan blue to assess their viability. To further cultivate the cells, 1.5 million cells 
were seeded into a T75 flask. For experimental purposes, 50,000 cells per well were added into 
each well of the 24-well coated plates. 
3.2.5.2 Transient transfection  
After seeding, the cells were allowed to grow for four days before the transfection was performed. 
HMEC-1 cells were transfected transiently with 250 ng of two plasmids, a pcDNA3 plasmid 
enabling the expression of the wild-type or mutated ETA receptor and a plasmid containing a 
reporter specific to NFAT or SRF. Transfection was performed in starvation medium using the 
XfectTM Transfection Reagent following the manufacturer’s instructions. 16 hours later, medium 
was changed to complete medium. 
3.2.5.3 Cell stimulation 
To study the functionality of the receptors, ET-1 and ETAR-IgG were used to stimulate the 
transfected cells. 48 hours after transfection, the medium was changed to starvation medium. One 
hour later, cells were treated with ET-1 (100 nM) or ETAR-IgG (1.0 mg/mL) or DMEM Low 
Glucose as controls. 
3.2.5.4 Luciferase measurement 
After six hours of stimulation, cells were washed once in PBS and lysed with 1X PLB for 15 
minutes under shaking. Luciferase quantity was assessed with the Luciferase Reporter Kit 
according to the manufacturer’s instructions and measured in a FLUOstar microplate reader using 
the OPTIMA software. 
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3.2.6 Statistical analysis 
Data are expressed as mean ± SEM, n stands for the number of independent experiments. 
Comparison between wild type non-stimulated and other groups were analyzed by Wilcoxon test; 
the other comparisons were performed by Mann-Whitney U test. Differences were considered 
significant when one-tailed tests p value was smaller than 0.05. GraphPad Prism software version 




4.1 Generation of human Endothelin-1 type A receptor mutants 
The extracellular loops (ECL) of ETAR are potential binding sites for patients’ antibodies, thus 
mutants of the ECL regions of ETAR to Alanine were generated to test their involvement in the 
receptor immune activation. 
4.1.1 Generation of yeast expressing ETA wild-type and mutant receptor 
The p426 GPD plasmid allows the expression of a gene of interest in yeasts. The ampicillin 
resistance gene expressed by the plasmid enables selection in E. coli (Figure 4). Three constructs 
had been previously generated in the p426 GPD plasmid in the lab: the human wild-type ETAR 
(ETAR WT), a mutant in which the first ECL of human ETAR was substituted for Alanine (ETAR 
ECL1 Ala) and a mutant where ETAR second ECL was replaced by the second ECL of AT1R 
(ETAR with ECL2 of AT1R, [Development of a molecular toolbox to study the cross-talk between 
Angiotensin II type 1 and Endothelin-1 type A receptors in the context of obliterative vasculopathy, 
http://www.diss.fu-berlin.de/diss/receive/FUDISS_thesis_000000100230]). 
 
Figure 4. Map of p426 GPD (6606 base pairs). 
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In order to mutate the third extracellular loop of ETAR to Alanine, a site-directed mutagenesis was 
realized. PCR amplification was performed using the p426 GPD ETAR WT construct as template 
and primers were specially designed for site-directed mutagenesis (Table 1). After transformation, 
the plasmid was purified and DNA was sequenced. As shown in figure 5, the third ECL of ETAR 
was correctly substituted to Alanine. 
 
Figure 5. Mutation of ETAR ECL3 to Alanine. (A) DNA Sequence of the third ECL of ETAR wild type and mutant. 
(B) Amino acid translation of the sequences. Mismatches are shown in red. 
4.1.2 Generation of mammalian cells expressing ETA wild-type and                    
mutant receptor 
The pcDNA3 plasmid (Figure 6) was used to express the human Endothelin-1 type A receptor in 
mammalian cells. The ampicillin resistance gene in the plasmid allows selection in E. coli.  
 
Figure 6. Map of the pcDNA3 plasmid (5446 base pairs). 
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HindIII and XhoI restriction enzymes were used to linearize the plasmid. PCR primers were 
designed with 5’ 15-bp extensions homologous to the ends of the linearized vector and p426 GPD 
ETAR constructs were used as templates. The appropriate insert and the linearized plasmid were 
ligated and transformed into E. coli. 
4.1.2.1 Generation of pcDNA3 ETAR WT 
Digestion of pcDNA3 ETAR WT with the two cloning enzymes, HindIII and XhoI, should produce 
three fragments, one 82 base pair (bp)-long fragment and one 5364 bp-long corresponding to the 
pcDNA3 plasmid, one 1281 bp-long fragment corresponding to human ETAR. Figure 7 shows 
plasmids of ten ampicillin resistant colonies obtained after cloning. All plasmids showing two 
bands of the right size were considered positive as the 82 bp-long fragment was too small to be 
detected. 
 
Figure 7. Double digestion of ten ampicillin-resistant colonies. Plasmids 2 to 10 are positive. 
In order to verify the absence of mutations, the positive plasmids were sequenced and aligned with 
the sequence of the template. Two positive plasmids without any mutations were chosen to perform 
the luciferase reporter assays. 
4.1.2.2 Generation of pcDNA3 ETAR ECL1 Ala 
The p426 GPD ETAR ECL1 Ala construct was used as template to sub-clone the ETAR ECL1 Ala 
fragment to pcDNA3. Six colonies obtained after transformation were picked and verified by 
double digestion, as done for wild type ETAR. All colonies showed two bands, corresponding 
respectively to the linearized pcDNA3 plasmid and the insert (Figure 8). One clone was completely 
sequenced (Figure 9) and was used in further cell experiments. 
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Figure 8. Double digestion of plasmids from colonies potentially containing the pcDNA3 ETAR ECL1 Ala plasmid. 
 
Figure 9. Mutation of ETAR ECL1 to Alanine. (A) Sequence of the first ECL of ETAR wild type and mutant. (B) 
Amino acid translation of the sequences. Mismatches are shown in red. 
4.1.2.3 Generation of pcDNA3 ETAR with ECL2 of AT1R and pcDNA3 ETAR ECL3                                                                          
Ala 
These sub-cloning experiments were made using the same protocol as that used for the ECL1 
mutant. In each case, from the positive plasmids found after double digestion, one was completely 
sequenced (Figure 10 and 11) and used for luciferase assays if it was free of mutations. 
 
Figure 10. Mutation of ETAR with ECL2 of AT1R. (A) Sequence of the second ECL of ETAR and AT1R wild type. (B) 
Amino acid translation of the sequences. 
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Figure 11. Mutation of ETAR ECL3 to Alanine. (A) DNA Sequence of the third ECL of ETAR wild type and mutant. 
(B) Amino acid translation of the sequences. Mismatches are shown in red. 
4.2 Effects of the structure of the extracellular loops on ETAR activation 
In order to study the influence of the structure of each extracellular loop on ETAR activation, a 
GPCR activation assay already established for previous yeast batches in the lab was applied 
[Development of a molecular toolbox to study the cross-talk between Angiotensin II type 1 and 
Endothelin-1 type A receptors in the context of obliterative vasculopathy, http://www.diss.fu-
berlin.de/diss/receive/FUDISS_ thesis_000000100230]. This assay had to be first optimized for 
novel experimental conditions. 
4.2.1 Optimization of the GPCR activation assay  
In the MMY yeast model, the yeast’s growth depends on the activation of the expressed human 
GPCR. Dependent on the kind of receptor transformed, several parameters had to be optimized. 
4.2.1.1 Optimization of MMY yeast transformation 
The first step was to improve MMY yeast transformation, first, by determining the optimal plasmid 
amount. Total RNA extracted from transformed or non-transformed yeast cells was subjected to 
RT-PCR to obtain cDNA. Then, quantitative RT-PCR was performed to determine the human 
ETAR wild-type expression level. After normalization to yeast GAPDH, the ETAR expression level 
was calculated as relative to control (non-transformed yeasts). Results showed that transformation 
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with 0.5-µg plasmid achieved the lowest expression, 3-µg the best (Figure 12A). Then, optimal 
incubation times after transformation were investigated to obtain high ETAR transcription levels. 
As shown in figure 12B, yeasts transformed with 1-µg plasmid and incubated for four days had 
the highest receptor expression level. Therefore, this condition was used in further experiments. 
 
Figure 12. ETAR wild-type transcription level in yeast (A) Yeasts were transformed with different amounts of plasmid 
and incubated for three days. (B) Yeasts were transformed with different amounts of plasmid and incubated for three 
or four days after transformation. Values are from three colonies and presented as mean ± SD. 
4.2.1.2 Optimization of the GPCR assay 
Three parameters were further modulated to optimize the GPCR assay: the first is 3-AT (3-amino 
triazole), which is a competitive inhibitor of the HIS3 protein moderating background yeast growth 
caused by leakiness of the receptor or constitutive activity of the GPCR [51]. The second, the way 
to inoculate the yeast cultures before the assay and the third parameter is the seeding density of 
the yeast cells into the assay medium, which can also influence the outcome of the assay. All three 
parameters were tested but only the way of inoculation of the yeast cultures showed effects. 
For the first inoculation method, single colonies were picked with a sterile toothpick 72 hours after 
transformation, streaked onto a WHAUL+His plate for further 24 hours and then scraped and 
inoculated into 200 µL of WHAUL+His medium. For the second method, transformed yeast clones 
were picked after four days and single colonies were directly inoculated into 100 µL of 
WHAUL+His. In each case, yeast cells grown overnight in WHAUL+His were stimulated with 
ET-1 in increasing concentrations: 0, 10-7, 5*10-7 and 10-6 M. As shown in figure 13, the second 
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inoculation way gave the strongest fluorescence intensity and showed a dose-dependent activation 
of ETAR upon stimulation with ET-1. 
 
 
Figure 13. Yeast growth after ET-1 stimulation. Two methods of inoculation were compared. Yeast growth is reflected 
by the fluorescence intensity. Ten wells of a single colony were measured and the data are presented as mean ± SD. 
4.2.2 ETAR activation by ETAR-IgG and involvement of the 
extracellular loops 
MMY14 strain expressing Gq/11 was transformed with p426GPD ETAR WT or mutant. In this 
model, it has already been shown that ET-1 activates ETAR dose-dependently [Development of a 
molecular toolbox to study the cross-talk between Angiotensin II type 1 and Endothelin-1 type A 
receptors in the context of obliterative vasculopathy, http://www.diss.fu-
berlin.de/diss/receive/FUDISS_thesis_000000100230]. Therefore, the focus was on the IgG-
mediated activation of the receptor. Yeasts were stimulated with increasing concentrations of 
ETAR-IgG (0, 0.5, 1 and 1.5 mg/mL) isolated from systemic sclerosis (SSc) patients tested positive 
for ETAR-IgG in ELISA. After 16 hours of incubation, fluorescence intensity was measured. 
4.2.2.1 ETAR-IgG activate the wild-type receptor 
When the yeast cells were stimulated with ETAR-IgG after transformation with the wild-type 
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receptor, the yeast growth increased significantly when comparing stimulated yeasts to non-
stimulated yeasts (Figure 14). Therefore, IgG isolated from patients was able to induce activation 
of the receptor. 
 
Figure 14. MMY 14 ETAR wild-type yeast growth in GPCR activation model stimulated with ETAR-IgG. Yeast growth 
is depicted as relative to yeast growth without stimulation. Data are from six experiments and presented as mean ± 
SEM, * p < 0.05. 
4.2.2.2 Involvement of the extracellular loops in ETAR activation 
4.2.2.2.1 The second extracellular loop is not involved in ETAR activation 
A thesis done in the laboratory had already shown that the second extracellular loop was not 
necessary for the receptor activation [Development of a molecular toolbox to study the cross-talk 
between Angiotensin II type 1 and Endothelin-1 type A receptors in the context of obliterative 
vasculopathy, http://www.diss.fu-berlin.de/diss/receive/FUDISS_thesis_000000100230]. Hence, 
the focus of this study was on the first and third loops. 
4.2.2.2.2 The first extracellular loop is involved in ETAR activation 
Yeast expressing the receptor mutated in the first ECL showed a trend to a higher growth rate even 
without antibodies stimulation. Increasing the concentrations of the stimuli did not bring any 
further activation in yeasts expressing the mutant receptor (Figure 15), suggesting that there could 
be a constitutive activation of the receptor due to the modification of the first ECL structure. 
 51 
 
Figure 15. Yeast growth in GPCR activation model stimulated with ETAR-IgG. Yeast growth is depicted relative to 
yeast growth without stimulation. Data are from six (WT) and four (ECL1) experiments and presented as mean ± 
SEM, * p < 0.05, **p < 0.01. 
4.2.2.2.3 Mutating ECL3 results in ETAR constitutive activation 
As for the third ECL, mutation to Alanine induced a significantly stronger yeast growth already in 
absence of immune stimulation (Figure 16), which means that there is a constitutive activation of 
the mutated receptor. 
 
Figure 16. Yeast growth in GPCR activation model stimulated with ETAR-IgG. Yeast growth is depicted relative to 
yeast growth without stimulation.  Data are from six (WT) and seven (ECL3) experiments and presented as mean ± 




4.3 Extracellular loops of ETAR trigger G-protein activation 
To investigate whether structural changes affecting extracellular loops of ETAR induce the same 
effects in a more complex environment as in the MMY model, activation of G-proteins upon 
stimulation of ETAR was monitored. Human Endothelin-1 type A receptor binds to two G-proteins, 
Gq/11 and G12/13, upon activation by its peptide agonist, ET-1 [9]. In order to characterize the 
intracellular pathways activated after receptor stimulation with IgG and to determine involvement 
of specific extracellular loops, the mutants used in the yeast assay were subcloned in pcDNA3 to 
allow their expression in mammalian cells. 
Gq/11 and G12/13 activation was monitored in luciferase reporter assays by measuring the binding 
of the transcription factors NFAT (Nuclear factor of activated T-cells) and SRF (Serum response 
factor), respectively to DNA. Human microvascular endothelial cells (HMEC-1) were transiently 
transfected to express either wild-type or mutated ETAR and a NFAT or SRF luciferase reporter 
plasmid. Cells were stimulated with the peptide agonist of the receptor, ET-1, or ETAR-IgG. 
4.3.1 G-protein activity is increased upon ETAR WT activation 
In the NFAT luciferase reporter assay, cells transfected with wild-type ETAR showed a significant 
increase in NFAT activity in response to both ET-1 and ETAR-IgG stimulation, antibodies inducing 
a slightly higher increase than the peptide agonist (Figure 17A). This result was concordant with 
those previously obtained in yeasts. 
Furthermore, cells transfected with wild-type ETAR showed that ET-1 and ETAR-IgG both 
significantly increased SRF activity. IgG-mediated activation of the receptor induced a 
significantly stronger activation of G12/13 than ET-1 (Figure 17B). In conclusion, antibodies 
stimulating ETAR trigger a higher activation of both Gq/11 and G12/13 than does the peptide agonist. 
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Figure 17. Relative NFAT activity (A) and SRF activity (B) in response to ET-1 and ETAR-IgG stimulation in HMEC 
cells transfected with ETAR wild-type. NFAT or SRF activity is depicted relative to NFAT or SRF activity in absence 
of stimulation, respectively. Data are from nine (NFAT) and eleven (SRF) experiments and presented as mean ± SEM, 
* p < 0.05, **p < 0.01, *** p < 0.005. 
4.3.2 The second extracellular loop of ETAR is required for ET-1 but not           
for IgG-induced G-protein activation  
In the yeast GPCR activation assay, replacing the second extracellular loop of ETAR by ECL2 of 
AT1R did not affect endogenous or IgG-mediated activation of the receptor [Development of a 
molecular toolbox to study the cross-talk between Angiotensin II type 1 and Endothelin-1 type A 
receptors in the context of obliterative vasculopathy, http://www.diss.fu-
berlin.de/diss/receive/FUDISS_thesis_000000100230]. In order to verify these results in 
mammalian cells, this mutant was used in both NFAT and SRF luciferase reporter assay. 
When the cells were transfected with pcDNA3 ETAR with ECL2 of AT1R, stimulation with ETAR-
IgG led to significantly increased NFAT activity in comparison to non-stimulated cells (Figure 
18A). Stimulation with ET-1 also showed a slight increase of NFAT activity, but it was not 
significant. This confirms the results observed in yeast. However, it should be noted that the Gq/11 
activation upon antibodies stimulation was stronger in the mutant cells than in the wild-type cells, 
something that was not seen in yeasts. 
In SRF luciferase reporter assay, cells that were transfected with pcDNA3 ETAR with ECL2 of 
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AT1R and stimulated with ET-1 showed SRF activity at non-stimulated level, revealing that intact 
ECL2 structure is essential for ETAR activation via its peptide agonist. Conversely, cells 
transfected with ETAR mutant and stimulated with ETAR-IgG showed a higher activity of SRF in 
comparison to both non-stimulated wild-type and mutant ETAR transfected cells, even if 
significance was only found with wild type (Figure 18B). Hence, ECL2 does not seem necessary 
for antibody-triggered ETAR intracellular signaling. 
 
Figure 18. Relative NFAT activity (A) and SRF activity (B) in response to ET-1 and ETAR-IgG stimulation in HMEC 
cells transfected with ETAR wild type and ETAR with AT1R ECL2. NFAT or SRF activity is depicted relative to NFAT 
or SRF activity in absence of stimulation, respectively. Data are from eleven (WT) and seven (ECL2) experiments 
and presented as mean ± SEM, * p < 0.05, ** p < 0.01, *** p < 0.005. 
4.3.3 The first extracellular loop of ETAR is required for G12/13 activation 
Cells transfected with ETAR ECL1 Ala mutant and stimulated with ETAR-IgG showed a 
significantly higher activity of NFAT in comparison to non-stimulated wild type ETAR cells. 
However, no constitutive activation of the receptor was observed (Figure 19A). Hence, mutation 
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of the receptor’s first extracellular loop does not influence the activation of Gq/11 mediated by 
antibodies. 
When the cells were transfected with ETAR ECL1 Ala and stimulated with ET-1, SRF activity 
stayed at non-stimulated level and was significantly decreased in comparison to the stimulation of 
the wild-type receptors, revealing that normal structure of ECL1 is essential for ETAR-mediated 
G12/13 activation via its peptide agonist. Conversely, cells transfected with ETAR ECL1 Ala and 
stimulated with ETAR-IgG showed a significantly higher activity of SRF in comparison to non-
stimulated wild type ETAR and mutant transfected cells (figure 19B). Therefore, ECL1 is not 
necessary for antibody-triggered ETAR intracellular signaling. 
 
Figure 19. Relative NFAT activity (A) and SRF activity (B) in response to ET-1 and ETAR-IgG stimulation in HMEC 
cells transfected with ETAR wild type and ETAR ECL1 Ala. NFAT or SRF activity is depicted relative to NFAT or 
SRF activity in absence of stimulation, respectively. Data are from eleven (WT) and eight (ECL1) experiments and 
presented as mean ± SEM, * p < 0.05, ** p < 0.01, *** p < 0.005. 
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4.3.4 Mutation of the third extracellular loop results in constitutive  
binding of G-proteins  
When the cells were transfected with ETAR ECL3 Ala, a significant increase of NFAT activity in 
comparison to the wild-type ETAR transfected cells could already be seen in the absence of 
stimulation (figure 20A). This revealed a constitutive binding of Gq/11 to the receptor which was 
consistent with the results obtained in yeast experiments. 
As in the NFAT study, when the cells were transfected with ETAR ECL3 Ala, a significant increase 
of SRF activity could be seen in the absence of stimulation, revealing a constitutive binding of 
G12/13 to the mutated receptor (figure 20B). 
 
Figure 20. Relative NFAT activity (A) and SRF activity (B) in response to ET-1 and ETAR-IgG stimulation in HMEC 
cells transfected with ETAR wild type and ETAR ECL3 Ala. NFAT or SRF activity is depicted relative to NFAT or 
SRF activity in absence of stimulation, respectively. Data are from eleven (WT) and eight (ECL3) experiments and 




In this work, involvement of the Endothelin-1 type A receptor (ETAR) extracellular loops in the 
receptor activation and resulting intracellular signaling was investigated. IgG binding to ETAR 
triggered a stronger activation of Gq/11 and G12/13 signaling pathways as the natural peptide agonist 
ET-1. GPCR activation assay in yeasts using mutations of the extracellular loops of the receptor 
demonstrated that disturbing the third ECL structure might constitutively activate the receptor. 
Similar results were obtained in mammalian cells, where mutating ECL3 resulted in the 
constitutive binding of Gq/11 and G12/13 to ETAR. Furthermore, changes in ECL1 structure had only 
a small impact on ETAR-mediated Gq/11 pathway activation. On the other hand, without 
preservation of ECL1 structure, ETAR-triggered G12/13 activation after stimulation with ET-1 was 
lost. Replacement of the second extracellular loop of the receptor by ECL2 of AT1R confirmed 
that this domain is only involved in ET-1 induced G12/13 pathway activation. These results shed 
light on the influence of the extracellular loops on ETAR activation and show that antibodies bind 
to the receptor in a completely different way than the peptide agonist. 
 
Yeast GPCR activation assays, applications and models 
In this project, a yeast model was used to assess GPCR activation. The yeast mating pathway is 
often used to study GPCR activation and signal transduction. The yeast’s growth depends on 
activation of one single GPCR which can be replaced by a mammalian GPCR, which then activates 
a preserved pathway [52], providing an eukaryotic assay system with no other endogenous 
responses [51]. To activate the mating pathway, GPCRs must be coupled to a heterotrimeric G-
protein consisting of Ga (Gpa1), Gb and Gg. Compatibility between the receptor and the G-proteins 
depends on the C-terminus of the Ga subunit. It has been shown that the chimeric Ga subunit 
consisting of five C-terminal amino acids of a human G-protein fused with the yeast G-protein 
alters the specificity of Ga without disturbing the signal transduction [49]. Yeast Gb and Gg are 
homologous to mammalian Gb and Gg subunits, so that yeast Gbg may have close structural and 
functional similarities with mammalian Gbg subunits [53]. When an agonist binds to a receptor, the 
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Gbg subunit transduces signals to the mitogen-activated protein kinase (MAPK) cascade, resulting 
in cell cycle arrest and gene expression, as FUS1 for mating. The MMY system used in this study 
is based on the Saccharomyces cerevisiae strain that uses FUS1 as a pheromone-responsive 
promoter and the HIS3 gene as a reporter. HIS3 encoding the key enzyme that produces histidine, 
an essential amino acid for yeast growth, is located behind the FUS1 promoter. As a result, only 
the cells, in which the human GPCR is activated, can grow in histidine-free selective medium. 
Experiments have already been performed in the MMY system to study different GPCRs. The role 
of the second and third extracellular loops of the adenosine A1 receptor was studied using the 
MMY24 strain, which expresses chimeric Gpa1/Gai3. By Means of Alanine scan, the authors 
demonstrated a strong regulatory role for the ECL2 and the importance of many residues of ECL2 
and ECL3 for adenosine A1 receptor activation [54]. Furthermore, adenosine A2B receptor was 
investigated in the MMY24 strain. Random mutagenesis was introduced in transmembrane 
domains four and five. The screening identified 22 single and double mutant receptors showing 
constitutive activity and decreased agonist potency [55]. Many features of the MMY model enable 
rapid analysis of structural and functional aspects of GPCRs. However, this is not the only existing 
yeast model to study GPCRs. One of the difficulties in using the yeast system to analyze the 
signaling of human GPCR is that the coupling between a yeast G-protein and a human GPCR can 
be ineffective and results in poor signal transduction. Hence, Fukuda et al. described a novel 
strategy for increasing the sensitivity of agonist-mediated signal transduction of human GPCR 
expressing yeast [56]. Stimulation of ligand induces the expression of both GFP, a reporter gene, 
and Gb gene. Overexpressed Gb competes with endogenous Gb present in the Gabg heterotrimer for 
Ga binding, wherein the free Gbg complex can further activate the MAPK cascade and amplify the 
signal. In parallel, Li et al. described a novel yeast genetic screen that only selects for mutant 
receptors containing inactivation point mutations that is capable of identifying single-point 
mutations that abolish the receptor function [57]. The yeast strain contains the pheromone-
sensitive FUS2-CAN1 reporter gene encoding the cytotoxic arginine-canavanine permease. Yeasts 
expressing a functional receptor in the presence of an agonist will not grow, while yeasts 
expressing a mutant containing inactivating point mutation in a medium containing both carbachol 
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and canavanine will grow. 
 
Constitutively active mutants (CAMs) of GPCRs 
Using the MMY yeast model, binding of ETAR-IgG to the extracellular domains of ETAR was 
observed. Interestingly, mutation of ECL3 led to a constitutive activation of ETAR. Constitutive 
receptor activation is defined as the spontaneous formation of a signaling conformation of a 
receptor, resulting in the production of a second messenger without agonist binding [58]. ECL3 is 
usually a short loop, so it can constrain TM6 and TM7, limiting their movement and maintaining 
the receptor’s ground state [59]. Substitution in ECL3 relieves this limitation and may affect the 
conversion of ground state into active state [59]. The ECL3 of b2-adrenergic receptor (b2AR) 
replaced by the ECL3 of the a1aAR, has a higher binding affinity to agonists and a higher agonist-
independent basic adenylyl cyclase activity compared to the wild type b2AR, with no influence on 
the affinity to antagonist [60]. In contrast, replacement of the ECL3 of the TSHR by the ECL3 of 
the b2AR did not affect the basal signaling, but decreased the potency and extent of the TSH-
stimulated cAMP response [61]. Other constitutive mutations have been described in GPCRs. The 
mutation of Asn2957.46 to Ala was involved in the constitutive activation of AT1R, probably due to 
the disruption of two hydrogen bonds between Asn2957.46 and Asn1113.35, which stabilize the 
inactive conformation [62]. Asn111 in TM3 helix plays a central role in AT1R activation through 
direct interaction with the Tyr4 side chain of Ang II [63].  
 
Role of ECL1 and ECL2 in other GPCRs 
Further new insights from thesis work are that ECL1 and ECL2 of ETAR are necessary for ET-1-
induced intracellular signaling activation. Crystal structure of Endothelin-1 type B receptor was 
recently published [11]. As ETAR and ETBR vary a lot in their amino acid sequences, it is difficult 
to draw conclusions from this structure. However, some studies showed the importance of these 
two ECLs in ET-1 binding to the ETA receptor. Substitution of ECL1 of ETAR with the ETB 
counterparts significantly reduced the antagonist binding of BQ-123, indicating that the ECL1 is 
important for binding [64]. Mutations of Gly97, Lys140, Lys159, Gln165 and Phe315, each 
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located in TM 1,2,3,3 and 6, result in decreased radio-ligand binding to receptor, which has similar 
levels expressed in cells [13]. In contrast to its involvement in ET-1 binding, mutational studies 
indicated that ECL2 is not involved in the binding of IgG to ETAR. This is different to other studies 
on GPCRs and antibodies. Magnusson et al. demonstrated that the specific target of stimulatory 
autoantibodies in patients with dilative cardiomyopathy was the second extracellular loop of the 
b1AR [65]. Chiale et al. confirmed the finding that the autoantibodies bind to the second 
extracellular loop of the b1AR, and they identified agonistic autoantibodies to b2AR [66]. In 
addition, Unal et al. demonstrated that the conformational kinetics of the ECL2 of AT1R produce 
an epitope for AT1R autoantibodies [67]. This allows the antibodies to bind and stabilize the active 
state of AT1R. Epitope mapping studies in human AT1R revealed that autoantibodies in patients 
with preeclampsia bind to epitope “AFHYESQ”, the autoantibodies in patients with malignant 
hypertension and refractory vascular allograft rejection recognize and bind to are epitopes 
“ENTNIT” and “AFHYESQ” [68].  
 
Putative pathogenic mechanisms for Gq/11 and G12/13 activation 
Interestingly, antibodies binding to the ETAR elicited a much stronger Gq/11 and G12/13 activation 
compared to the binding of the peptide agonist ET-1. This could be responsible for many aspects 
of pathophysiology of systemic sclerosis. SSc is characterized by abnormal vascular alterations, 
endothelial cell injury considered as a crucial initiating event leading to vascular remodeling. It 
has been shown that dysregulation of apoptosis is associated with this process [69]. Apoptosis is 
a highly conserved cellular mechanism characterized by cell shrinkage, chromatin condensation 
and nuclear fragmentation. It occurs under many physiological and pathophysiological conditions 
[70]. Increased endothelial apoptosis has been shown to represent the earliest microvascular 
abnormality in SSc animal models, suggesting that endothelial cell apoptosis is the initial trigger 
[71] [72]. Endothelial cell apoptosis has been observed under various pathogenic conditions in 
vivo and can be induced in vitro by anti-endothelial cell antibodies in systemic sclerosis [73] [74]. 
Apoptosis in HeLa cell can be induced by overexpression of active Gq/11 or stimulation of M1 
muscarinic acetylcholine receptor [75]. One study confirmed the importance of Gq/11 and PKC in 
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Angiotensin II-induced myocyte apoptosis [76]. The MAP kinase pathway is also involved in the 
regulation of apoptosis. Two related MAPK kinases, apoptosis signal-regulation kinase 1 (ASK1) 
and MAPK kinase kinase 1 (MEKK1), stimulate c-Jun kinase (JNK) activity and induce apoptosis. 
In COS-7 cells, G12/13 stimulated the JNK pathway in an ASK-1 and MEKK1-dependent manner 
during apoptosis [77]. ET-1 may also promote the proliferation of vascular smooth muscle cells 
and fibroblasts, causing vascular wall thickening [78] [79]. AT1R-IgG and ETAR-IgG specifically 
bind to their receptors on endothelial cells, induce phosphorylation of ERK1/2 and increase the 
gene expression of TGF-b, indicating their potential involvement in fibrosis [35]. This process 
could involve G12/13. The G12/13 subfamily is of great significance in mediating signaling pathways 
such as Rho/Rho-associated protein kinase (ROCK)-dependent formation of actin stress fibers [80] 
and in vascular smooth muscle cell contraction [81], suggesting that the G12/13 subfamily may play 
a considerable role in various physiological effects ET-1 induced such as cell growth, migration, 
transformation and gene expression. 
 
The results generated in this work show the involvement of the first and second extracellular loops 
of Endothelin-1 type A receptor in ET-1-induced receptor activation. On the contrary, binding of 
ETAR-IgG does not rely on the presence of intact ECL1 to 3 and activates Gq/11 and G12/13 more 
strongly than ET-1. Further studies are required to determine if other extracellular domains of 
ETAR, like the N-terminus, are involved in the binding of the antibodies to the receptor. These 
results constitute the first step towards a better understanding of ETAR immune activation and 
towards designing new drugs able to impair it specifically.  
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